MeCP2 as an Activator of Gene Expression

Patricia M Horvath; Lisa M Monteggia

doi:10.1016/j.tins.2017.11.005

MeCP2 as an Activator of Gene Expression

Trends Neurosci. 2018 Feb;41(2):72-74. doi: 10.1016/j.tins.2017.11.005.

Authors

Patricia M Horvath¹, Lisa M Monteggia²

Affiliations

¹ Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, TX 75390-9111, USA.
² Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, TX 75390-9111, USA. Electronic address: lisa.monteggia@utsouthwestern.edu.

Abstract

Rett syndrome is a neurodevelopmental disorder that primarily affects females and is caused by mutations in the methyl-CpG-binding-protein 2 (MECP2) gene. Initially, MeCP2 had been shown to be a repressor of gene transcription. In their 2008 paper, Chahrour and colleagues (DOI: 10.1126/science.1153252) reported that MeCP2 could also function as a transcriptional activator.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Gene Expression / genetics*
Genetic Predisposition to Disease*
Humans
Methyl-CpG-Binding Protein 2 / genetics*
Mutation / genetics*
Phenotype
Rett Syndrome / genetics*

Substances

Methyl-CpG-Binding Protein 2

Abstract

Publication types

MeSH terms

Substances

Grants and funding